SYDNEY--(BUSINESS WIRE)--Following the merger of private drug developer Hunter Immunology Limited with Probiomics Limited (ASX: PCC), the merged entity today recommenced trading on the Australian Securities Exchange (ASX). The business will initially continue to trade as and intends to rename as Bioxyne (ASX: BXN) in coming weeks. At the commencement of trading, the company had a market cap of over $33 million with 149.9 million shares.
